Thanks to a grant from an Australian foundation called the Charlie Teo Foundation, a local drug discovery venture will now progress an investigational product to pre-clinical efficacy testing for glioblastoma (GBM), the most common form of brain cancer with an average survival rate of only 15 months from diagnosis. Now Pharmaxis (ASX:PXS) will receive a $AUD 186,837 research grant, which will be distributed to Alan Y. Wang, PhD, associate professor of Cancer Biology at the University of Texas, MD Anderson Cancer, to enable study of PXS-5505. Worldwide, it’s estimated there are more than 300,000 cases of brain and nervous system tumours each year with GBM being the most common form.
But What is PXS-5505?
As recently shared in the company’s press release, Pharmaxis shared that Lysyl oxidase enzymes play a crucial role in GBM because they attract inflammatory cells that accelerate tumour growth and reduce survival.
PXS5505 is a potent inhibitor of lysyl oxidases and should stop these processes. Pharmaxis’ drug has demonstrated a good safety profile in healthy volunteer clinical studies in Australia. Previous research has already shown the importance of lysyl oxidases t...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).